Old API Wind-down Ltd - Ordinary Shares ARLZQ

Yosprala Approval

[2quick154]

It has been a pretty frustrating time for us since the merger... Now it finally looks like things are heading in the right direction and It seems Yosprala will be approved.

If we get a big jump on approval, it will be tough not to bail out considering the ride we have had... Any thoughts?

[kuatolives]

My thoughts are we'd be rich if Harris hadn't sold out Tribute shareholders the way he did. Thanks again Rob you putz. Tribute earnings continue to be strong and continue to grow.  It'll be hard for me to let this go as I knew the merger was a bad idea. ANYWAY, it looks like revenue is now growing and losses narrowing, so we're moving in the right direction.  Once

[Bigboyone]

Yes I do agree, & happy to see a nice day on earnings.. its a step in the right direction, but before we all start clapping, lets see where we close today (Above $4.00?).Do the $4.00 sellers from yester put a clamp on it at days end..?.remember, I am not one to put a bad note on anything , last year our T-BUFF shares where worth aprox $1.50+ at this time, That would be equal to ARALEZ at ..$11

[Floridas2000]

Depends on the type of investor you are.  Do you want to gain a small percentage, sell and move on to the next stock or do you want to go long and hope for a certain multiple?  Do you need the money now or you can park it.   The turnaround is just starting.  Their strategy of having dedicated saleforce targetting certain sellers is working and is a good sign for Yosprala going

[kuatolives]

Agreed, I can't forsee anyone who has stuck it out this long to sell once the turnaround has started and a break even point (hopefully) somewhere on the near horizon.  You'll always get your daily buyers and sellers that will move the price on a daily and weekly basis, but with the last earnings session out of the way before the Yosprala annoucement, sentiment should generally be

[felix10]

The conference call was good. They said they would expect to be profitable by 2018 even without Yosprala. Expenses will be up in the second half of this year as they hire a lot more salespeople assuming Yosprala is approved.  Sounded like they aren't actively looking for acquisitions, but wouldn't rule them out if the right one comes along. I couldn't really understand their

[kuatolives]

I'm glad they're not on the hunt for some new acquisition but rather focusing on their core business, at least unless some golden goose comes along. The last thing shareholders need is some boneheaded acquisition that piles on the debt and annoys investors just so they can increase the bottom line - which Valeant, CXR, Merus etc, have shown produces limited, if any, long term shareholder

[Floridas2000]

They're complaining this quarter's Aralez numbers with last year's Pozen numbers excluding Tribute.  This quarter should have Tribute's numbers in it, in fact did someone see if Tribute's revenue increase this last quarter?  I'm expecting it did.    And they expect to break even without Yosprala??  So 2017 with Yosprala most likely, this stock

[kuatolives]

I liked the conference call inasmuch as they're treating it very professionally.  Nice to see Fibricor Rx's responding to the new salesforce, and its also good they're not just targetting any old bozo physician, but physicians more likely to perscribe yospralla, once launched. Some other positives: -Revenues should only expand from here and costs only shrink, but we'll see

[GoldenDilemma]

If we head towards 200MA, and break this 4.4 zone (ARLZ chart), smooth sailing on approval. 

[GoldenDilemma]

Image did not insert so here it is: https://imgur.com/a/EeDxh